Irritable bowel syndrome: recent and novel therapeutic approaches (Q36514156)

14 August 2017

1 reference

title

Irritable bowel syndrome: recent and novel therapeutic approaches (English)

1 reference

14 August 2017

irritable bowel syndrome

1 reference

2

Michael Camilleri

1 reference

14 August 2017

Viola Andresen

1

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

66

1 reference

14 August 2017

8

1 reference

14 August 2017

1073-1088

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666080-00004

14 August 2017

0 references

cites work

Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome

1 reference

12 December 2020

Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo

1 reference

12 December 2020

Serotonergic modulation and irritable bowel syndrome

1 reference

12 December 2020

Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters

1 reference

12 December 2020

Cholecystokinin receptors

1 reference

12 December 2020

Structure of cholecystokinin receptor binding sites and mechanism of activation/inactivation by agonists/antagonists.

1 reference

12 December 2020

Potent NK1 antagonism by SR-140333 reduces rat colonic secretory response to immunocyte activation

1 reference

12 December 2020

AGA technical review on irritable bowel syndrome

1 reference

12 December 2020

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

1 reference

12 December 2020

Tachykinins in the gut. Part I. Expression, release and motor function

1 reference

12 December 2020

Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study

1 reference

12 December 2020

Prebiotics promote good health: the basis, the potential, and the emerging evidence

1 reference

12 December 2020

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Role of cholecystokinin in regulation of gastrointestinal motor functions

1 reference

12 December 2020

Physiology and pharmacology of corticotropin-releasing factor

1 reference

12 December 2020

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel

1 reference

12 December 2020

Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors

1 reference

12 December 2020

Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology

1 reference

12 December 2020

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

1 reference

12 December 2020

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

1 reference

12 December 2020

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist

1 reference

12 December 2020

A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation

1 reference

12 December 2020

Control of muscle tone in the human colon

1 reference

12 December 2020

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

1 reference

12 December 2020

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

1 reference

12 December 2020

Risk factors for colon ischemia.

1 reference

12 December 2020

Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study

1 reference

12 December 2020

Review article: clinical pharmacology of alosetron

1 reference

12 December 2020

Guanylin: an endogenous activator of intestinal guanylate cyclase

1 reference

12 December 2020

The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo

1 reference

12 December 2020

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

1 reference

12 December 2020

Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans

1 reference

12 December 2020

1 reference

12 December 2020

Plasticity in serotonin control mechanisms in the gut.

1 reference

12 December 2020

Contribution of NK(2) tachykinin receptors to propulsion in the rabbit distal colon

1 reference

12 December 2020

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

1 reference

12 December 2020

Muscarinic receptor subtypes. Physiology and clinical implications

1 reference

12 December 2020

Irritable bowel syndrome and probiotics: from rationale to clinical use.

1 reference

12 December 2020

Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans

1 reference

12 December 2020

Functional bowel disorders and functional abdominal pain

1 reference

12 December 2020

Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.

1 reference

12 December 2020

Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans

1 reference

12 December 2020

Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility

1 reference

12 December 2020

Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans

1 reference

12 December 2020

Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome

1 reference

12 December 2020

Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome

1 reference

12 December 2020

Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats

1 reference

12 December 2020

A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.

1 reference

12 December 2020

Management of the irritable bowel syndrome

1 reference

12 December 2020

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

1 reference

12 December 2020

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial

1 reference

12 December 2020

A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

1 reference

12 December 2020

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

1 reference

12 December 2020

Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study

1 reference

12 December 2020

Neurotrophin-3 improves functional constipation

1 reference

12 December 2020

Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea

1 reference

12 December 2020

Infection, immune function, and functional gut disorders

1 reference

12 December 2020

Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation

1 reference

12 December 2020

Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome

1 reference

12 December 2020

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

1 reference

12 December 2020

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

1 reference

12 December 2020

Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans.

1 reference

12 December 2020

Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study

1 reference

12 December 2020

Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in the irritable bowel syndrome.

1 reference

12 December 2020

Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro

1 reference

12 December 2020

Tegaserod for the treatment of irritable bowel syndrome

1 reference

12 December 2020

Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucous plexus

1 reference

12 December 2020

Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome

1 reference

12 December 2020

The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome

1 reference

12 December 2020

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

1 reference

12 December 2020

Tachykinin receptors in the gut: physiological and pathological implications

1 reference

12 December 2020

Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus

1 reference

12 December 2020

Lubiprostone: RU 0211, SPI 0211

1 reference

12 December 2020

Muscarinic receptors and gastrointestinal tract smooth muscle function

1 reference

12 December 2020

Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome

1 reference

12 December 2020

Cloning of a putative human voltage-gated chloride channel (CIC-2) cDNA widely expressed in human tissues

1 reference

12 December 2020

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.

1 reference

12 December 2020

Loxiglumide, a CCK-A Antagonist, in Irritable Bowel Syndrome

1 reference

12 December 2020

Treating irritable bowel syndrome: overview, perspective and future therapies

1 reference

12 December 2020

Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care

1 reference

12 December 2020

Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone

1 reference

12 December 2020

A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Postinfectious irritable bowel syndrome1 1Abbreviations used in this paper: EC,_; IBS, irritable bowel syndrome; PI, postinfective

1 reference

12 December 2020

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function.

1 reference

12 December 2020

Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery

1 reference

12 December 2020

ClC-2 in guinea pig colon: mRNA, immunolabeling, and functional evidence for surface epithelium localization

1 reference

12 December 2020

Irritable bowel syndrome patients show altered sensitivity to exogenous opioids.

1 reference

12 December 2020

Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome

1 reference

12 December 2020

Cholecystokinin-A receptor antagonists: therapies for gastrointestinal disorders.

1 reference

12 December 2020

Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome

1 reference

12 December 2020

Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health

1 reference

12 December 2020

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome

1 reference

12 December 2020

Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study

1 reference

12 December 2020

Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study

1 reference

12 December 2020

Excitation of rat colonic afferent fibres by 5-HT(3) receptors.

1 reference

12 December 2020

Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor.

1 reference

12 December 2020

Effects of morphine and atropine on motility and transit in the human ileum.

1 reference

12 December 2020

Pharmacological modulation of rectal tone alters perception of distention in humans.

1 reference

12 December 2020

Inhibition of small conductance K+ -channels attenuated melatonin-induced relaxation of serotonin-contracted rat gastric fundus

1 reference

12 December 2020

Mechanisms in IBS: something old, something new, something borrowed...

1 reference

12 December 2020

Role of CRF in stress-related alterations of gastric and colonic motor function

1 reference

12 December 2020

Selective postoperative inhibition of gastrointestinal opioid receptors

1 reference

12 December 2020

Differential regional effects of octreotide on human gastrointestinal motor function

1 reference

12 December 2020

Adrenergic modulation of human colonic motor and sensory function.

1 reference

12 December 2020

Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase

1 reference

12 December 2020

Escherichia coli heat-stable enterotoxins, guanylins, and their receptors: what are they and what do they do?

1 reference

12 December 2020

10.2165/00003495-200666080-00004

Identifiers

DOI

1 reference

PubMed ID

16789793

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16789793